Even under optimal treatment with anti-vascular endothelial growth factor (anti-VEGF), patients are exposed to an almost 50% risk of developing fibrosis within the first 2 years, especially in cases with Type 2 macular neovascularization (MNV) [4]. The gene discussed is VEGFA; the disease is fibrosis.